**Semaglutide Patent Expires: Major Generic Launches Transform Indian Market**
A significant development unfolded in India's pharmaceutical landscape as Sun Pharmaceuticals and Zydus Lifesciences launched their generic versions of semaglutide on the very first day of patent expiration. This milestone marks a pivotal shift in diabetes and weight management treatment accessibility across the nation.
Semaglutide, originally developed as a GLP-1 receptor agonist, has gained substantial clinical recognition for managing type 2 diabetes and obesity. The patent expiration now opens doors for multiple manufacturers to produce affordable alternatives, directly addressing the high cost barrier that previously limited patient access.
Sun Pharma and Zydus Lifesciences' rapid market entry demonstrates strong competitive positioning and manufacturing readiness.
